CHU Brugmann   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Brussels Belgium (1923)

Organization Overview

First Clinical Trial
2007
NCT00420277
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

CHU Brugmann | CHU-Brugmann | CHU Brugmann, Brussels | CHU Brugmann Dept Rheumatology, Brussels

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Agnosia (Phase 3)

Anemia, Sickle Cell (Phase 3)

Arthritis (Phase 2)

Arthritis, Psoriatic (Phase 2)

Behavior, Addictive (Phase 2)

Cocaine-Related Disorders (Phase 2)

Hyperalgesia (Phase 2)

Hypotension (Phase 3)

Ischemia (Phase 3)

Phantom Limb (Phase 2)

Squamous Intraepithelial Lesions of the Cervix (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 16
  • # of Trial APIs: 18